✦ LIBER ✦

Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers

✍ Scribed by Witzel, Isabell; Graeser, Monika; Karn, Thomas; Schmidt, Markus; Wirtz, Ralph; Schütze, Dina; Rausch, Alma; Jänicke, Fritz; Milde-Langosch, Karin; Müller, Volkmar

Book ID: 118737657
Publisher: Springer-Verlag
Year: 2013
Tongue: English
Weight: 434 KB
Volume: 139
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-013-1382-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Androgen receptor expression is a signif

Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers

✍ Isabella Castellano; Elena Allia; Valeria Accortanzo; Anna Maria Vandone; Luigi 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 420 KB

Higher expression of androgen receptor i

Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers

✍ Seho Park; Hyung Seok Park; Ja Seung Koo; Woo Ick Yang; Seung Il Kim; Byeong-Woo 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 268 KB

Alternation of Estrogen Receptor and Pro

Alternation of Estrogen Receptor and Progesterone Receptor Expression in Primary Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

✍ Dai Kitagawa; Shigehira Saji; Shin-ichiro Horiguchi; Yu Satoh; Kazumi Horiguchi; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 49 KB

Activated HER-receptors in predicting ou

Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy

✍ Mathilde S. Larsen; Karsten Bjerre; Anne E. Lykkesfeldt; Anita Giobbie-Hurder; A 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 382 KB

Phase 2 randomized trial of primary endo

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

✍ Vladimir F. Semiglazov; Vladislav V. Semiglazov; Garik A. Dashyan; Elena K. Zilt 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

## Abstract ## BACKGROUND. Few studies have compared primary neoadjuvant endocrine therapy with neoadjuvant chemotherapy in breast cancer patients. The need for preoperative chemotherapy with doxorubicin or taxanes may be reduced in postmenopausal patients with estrogen receptor (ER)‐positive and/

Persistently Elevated Chemokine Receptor

Persistently Elevated Chemokine Receptor CXCR4 in Primary Tumors Following Neoadjuvant Chemotherapy Is a Novel Predictive Molecular Marker for Patients with Locally Advanced Breast Cancer

✍ D.J. Hiller; C. Meschonat; P. Madumere; B.D. Li; Q. Chu 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 82 KB